Prevalence and outcome of diuretic resistance in heart failure
- 48 Downloads
Diuretic resistance (DR) is common in patients with decompensated heart failure (HF), and is associated with adverse outcomes. To determine the prevalence of DR and its impact on survival among patients with decompensated HF, we prospectively evaluated the prevalence and influence on prognosis of DR (defined as persistent congestion despite ≥ 80 mg of furosemide per day) in a cohort of elderly patients from the Spanish HF registry (RICA) admitted for an acute decompensation of HF. Patients with new-onset HF were excluded. From the global cohort of 2067 patients, 435 (21%; 95% CI 19.3%–22.7%) patients met criteria for DR. Patients with DR had more comorbidities (hypercholesterolemia, diabetes mellitus, valvular disease, chronic kidney disease, and cancer) and a worse functional status compared to patients without DR. In addition, patients with DR had a higher proportion of ischemic etiology, more advanced functional class and lower left ventricular ejection fraction values. After 1 year of follow-up, all-cause mortality was higher in patients with DR with an adjusted hazard ratio of 1.37 (95% CI 1.06–1.79; p = 0.018). The prevalence of DR in a cohort of elderly patients admitted for acute HF decompensation is 21%. DR is an independent predictor of 1-year mortality.
KeywordsHeart failure Diuretics Furosemide
we gratefully acknowledge all investigators who form part of the RICA Registry. This project was possible thanks to an educational unrestricted scholarship granted by Boehringer Ingelheim. We would like to thank RICA’s Registry Coordinating Center “S&H Medical Science Service” for their quality control data, logistic support, and administrative work and Prof. Salvador Ortiz, Universidad Autónoma de Madrid and Statistical Advisor S&H Medical Science Service, for the statistical analysis of the data presented in this paper.
This work was supported by an educational unrestricted scholarship granted by Boehringer Ingelheim.
Compliance with ethical standards
Conflict of interest
The authors declare that have no conflicts of interest.
Statements on human and animal rights
The registry complies with the Declaration of Helsinki. The local ethics committee from the University Hospital “Reina Sofia” (Córdoba, Spain) approved the study protocols.
Informed consent was obtained from all participating subjects.
- 1.Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT et al (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100, 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149:209–216CrossRefGoogle Scholar
- 5.Epstein M, Lepp B, Hoffman S et al (1997) Potentation of furosemide by metolazone in refractory edema. Curr Therap Res 21:656–667Google Scholar
- 8.Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200CrossRefGoogle Scholar
- 15.Trullàs JC, Morales-Rull JL, Casado J, Freitas Ramírez A, Manzano L, Formiga F (2016) Rationale and design of the “safety and efficacy of the combination of loop with thiazide-type diuretics in patients with decompensated heart failure (CLOROTIC) trial:” a double-blind, randomized, placebo-controlled study to determine the effect of combined diuretic therapy (loop diuretics with thiazide-type diuretics) among patients with decompensated heart failure. J Card Fail 22:529–536CrossRefGoogle Scholar
- 20.Ellison DH, Felker GM (2018) Diuretic Treatment in Heart Failure. N Engl J Med 378:684–685Google Scholar